Clinical trials: psoriasis
Psoriasis
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the…
- Trial name
- NCT00384098
- Testing
- CTA018 cream
- Where
- 16 sites in United States
- Volunteers
- 140 people
- Sponsor
- OPKO Health, Inc.
Psoriatic Arthritis
A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics
The purpose of this study is to conduct full psychometric testing of the Early Arthritis for Psoriatic Patients (EARP) questionnaire in Australian, Korean and Chinese populations
- Trial name
- PARIS (NCT02470481)
- Testing
- No Intervention
- Where
- 5 sites in Australia, China and 1 more
- Volunteers
- 250 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis Vulgaris
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03802344
- Testing
- MC2-01 cream, Cal/BDP combination, Vehicle
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 498 people
- Sponsor
- MC2 Therapeutics
Plaque Psoriasis
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.
- Trial name
- NCT06005532
- Testing
- Adalimumab, Humira
- Where
- 9 sites in Russia
- Volunteers
- 494 people
- Sponsor
- Mabscale, LLC
Plaque Psoriasis
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
This multicenter, randomized, double-blind, active-controlled study aims to evaluate the efficacy and safety of picankibart in Chinese patients with plaque psoriasis who demonstrated inadequate responses to interleukin-17 (IL-17)…
- Trial name
- NCT06945107
- Testing
- Picankibart, Secukinumab, Ixekizumab
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Plaque Psoriasis, Psoriasis
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body.
- Trial name
- NCT06357221
- Testing
- Cetaphil
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Psoriasis
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT07265284
- Testing
- IBI112
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Moderate-to-severe Chronic Plaque Psoriasis
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03463187
- Testing
- SHR-1314
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 211 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
- Trial name
- NCT05020249
- Testing
- bimekizumab
- Where
- 9 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- UCB Biopharma SRL
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Psoriasis
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06672393
- Testing
- HS-10374 6mg tablets
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Hansoh BioMedical R&D Company
Psoriatic Arthritis
A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
The purpose of this study is to evaluate treatment retention in psoriatic arthritis participants with STELARA or tumor necrosis factor alpha inhibitor (TNFi) therapies in relation to effectiveness, safety, benefit/risk and to…
- Trial name
- PsaBio (NCT02627768)
- Testing
- No Intervention
- Where
- 66 sites in Belgium, France and 5 more
- Volunteers
- 991 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Plaque Psoriasis
Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.
- Trial name
- NCT05268016
- Testing
- ME3183
- Where
- 27 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Meiji Pharma USA Inc.
Psoriasis Vulgaris
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
This trial is looking at whether the LEO 90100 foam causes irritation of the skin in healthy Japanese male adults without psoriasis.
- Trial name
- NCT03442244
- Testing
- LEO 90100 foam, Vehicle of LEO 90100 foam
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.
- Trial name
- NCT00098189
- Sponsor
- Novartis
Psoriasis Vulgaris, Plaque Psoriasis
Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient's individual application habits under daily use conditions.
- Trial name
- NCT01707368
- Testing
- Daivobet® Gel
- Where
- Germany
- Volunteers
- 561 people
- Sponsor
- LEO Pharma
Healthy, Atopic Dermatitis
A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests
The objective of this clinical study is to assess the irritation and sensitisation potential of HAT1 topical products after repeated patch applications to healthy human participants by following conventional Repeated Insult…
- Conditions
- Healthy, Atopic Dermatitis, Psoriasis
- Trial name
- NCT03406117
- Testing
- HAT1, Saline Solution
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Haus Bioceuticals
Psoriasis, Plaque Psoriasis
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPACT (NCT02346240)
- Testing
- Certolizumab Pegol, Etanercept
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 559 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriasis
Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Primary objective of this study is to compare patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI), two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form…
- Trial name
- NCT00482170
- Testing
- Enbrel (etanercept), Etanercept
- Where
- 78 sites in Belgium, Denmark and 10 more
- Volunteers
- 421 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.
- Trial name
- NCT01936337
- Testing
- DLX105 Hydrogel
- Where
- 3 sites in Austria, Germany
- Volunteers
- 59 people
- Sponsor
- Delenex Therapeutics AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.